Objectives: We performed a systematic review and meta-analysis to compare treatment effectiveness and adverse effects in cancer patients receiving chemotherapy with palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV).
Methods: We identified randomized controlled clinical trials (RCT) comparing palonosetron with first-generation 5-HT3RA in the prevention of CINV in cancer patients. Meta-analyses were performed on homogeneous studies. Fixed or random-effects models were used to combine data.
Results: Eight eligible trials were identified, reporting outcomes on 3,592 patients. Meta-analyses showed statistically significant differences in favor of palonosetron compared with first-generation 5-HT3RA in prevention of acute CINV (p = .0003), delayed CINV (p < .00001), and overall phase of CINV (p < .00001). Subgroup analyses showed statistically significant differences in favor of both 0.25 mg and 0.75 mg of palonosetron in prevention of all phases of CINV. There were no statistically significant differences between 0.25 and 0.75 mg of palonosetron. Compared with the first-generation 5-HT3RA, 0.75 mg of palonosetron showed a statistically significant difference in the occurrence of constipation (p = .04).
Interpretation: The use of palonosetron should be considered an integral part of adjuvant therapy for prevention of the acute, delayed, and overall phases of CINV. The 0.25 mg intravenous palonosetron dose is as effective as the 0.75 mg intravenous palonosetron dose. However, 0.75 mg intravenous palonosetron causes constipation more frequently than the first-generation 5-HT3RA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228089 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2010-0198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.
J Clin Oncol
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Purpose: Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate the efficacy and safety of HR20013 plus dexamethasone (DEX) versus fosaprepitant (FAPR) plus PALO + DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Methods: This is a noninferiority study.
A Comparative Study on the Efficacy of Intravenous Palonosetron Versus a Combination of Ondansetron and Dexamethasone as Prophylaxis for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Surgeries.
Cureus
October 2024
Department of Anaesthesiology and Critical Care, Sri Venkateshwaraa Medical College Hospital and Research Centre, Puducherry, IND.
Background: The most troublesome complaint after general anaesthesia and surgery, especially laparoscopic surgeries, is postoperative nausea and vomiting (PONV). We routinely use pharmacologic prophylaxis to prevent PONV. In patients undergoing laparoscopic procedures, we assessed the effectiveness of palonosetron compared to ondansetron combined with dexamethasone in preventing the incidence of PONV.
View Article and Find Full Text PDFA Randomized, Controlled Trial of Palonosetron Versus Ondansetron for Nausea, Vomiting, and Pruritus in Cesarean Delivery with Intrathecal Morphine.
Anesth Analg
October 2024
From the Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Spinal anesthesia is the preferred anesthetic technique for cesarean deliveries. Postoperative nausea and vomiting (PONV) and pruritus occur in up to 80% and 83% of patients, respectively, after cesarean delivery with intrathecal opioids. Ondansetron is the recommended medication for PONV prophylaxis, but palonosetron, a second-generation 5-HT3 receptor antagonist, has a higher receptor affinity and a longer half-life.
View Article and Find Full Text PDFEffect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial.
PLoS One
June 2024
Department of Anesthesiology and Pain Medicine, College of Medicine, Chung-Ang University, Seoul, South Korea.
Background: The aim of this study was to evaluate the impact of intravenous palonosetron compared to ondansetron on hypotension induced by spinal anesthesia in women undergoing cesarean section.
Methods: Fifty-four women scheduled for elective cesarean section were, randomly allocated to ondansetron group (n = 27) or palonosetron group (n = 27). Ten minutes prior to the administration of spinal anesthesia, participants received an intravenous injection of either ondansetron or palonosetron.
Vomiting in children and adolescents receiving intravenous pegaspargase: a retrospective study.
Pediatr Hematol Oncol
August 2024
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, USA.
Article Synopsis
- There is a lack of evidence regarding the emetogenicity (the ability to cause vomiting) of intravenous pegaspargase in pediatric patients, which prevented its classification in clinical guidelines.
- A retrospective study reviewed records of 44 pediatric patients treated with IV pegaspargase from 2011 to 2020, focusing on those who did not vomit after treatment.
- The findings showed that all 13 patients who received anti-nausea medications had a complete response, leading to the recommendation of classifying IV pegaspargase as moderately emetogenic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!